New agents to combat malaria

Nature Medicine

Volumn 7, Issue 2, 2001, Pages 149-150

  Beeson, James G ^a   Winstanley, Peter A ^b   McFadden, Geoffrey I ^a   Brown, Graham V ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; FANSIDAR; FATTY ACID SYNTHESIS INHIBITOR; HALOFANTRINE; MEFLOQUINE; PROGUANIL; QUININE; THIOLACTOMYCIN; TRICLOSAN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MALARIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); HUMANS; OXIDOREDUCTASES; PLASMODIUM FALCIPARUM; TRICLOSAN;

CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM;

EID: 0035129396     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/84573     Document Type: Short Survey

References (9)

1. World malaria situation in 1994
2. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum
3. Apicomplexan plastids as drug targets
4. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum
5. Broad spectrum antimicrobial biocides target the Fabl component of fatty acid synthesis
6. Mechanism of triclosan inhibition of bacterial fatty acid synthesis
7. Triclosan: Applications and safety
8. Pharmacokinetics of triclosan in rat after intravenous and intravaginal administration